We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Anti-Inflammatory Drug for Heart Disease

By Biotechdaily staff writers
Posted on 14 Mar 2003
An experimental drug that represents a new class of anti-inflammatory proteins is under investigation for the treatment of acute coronary syndrome.

The first human trial of this anti-inflammatory protein, VT-111, has been successfully completed by the developer, Viron Therapeutics, Inc. More...
(London, Canada). The trial assessed tolerability, safety, and pharmacokinetic properties. Currently, there are no anti-inflammatory drugs on the market that have been approved for the treatment of heart disease. Viron seeks to take advantage of this sizeable market opportunity.

"Viron is excited about the continued success of its lead compound VT-111,” said Mark Poznansky, president and CEO of Viron. "It is becoming increasingly clear that inflammation is a bigger predictor of heart attacks than even cholesterol.” Viron is a biotechnology company focused on the discovery and development of novel protein therapeutics for the treatment of human disease. The company was spun off from Robarts Research Institute (London, Canada).





Related Links:
Viron

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Aspiration System
VACUSAFE
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.